-
公开(公告)号：WO2010046097A1
公开(公告)日：2010-04-29
申请号：PCT/EP2009/007533
申请日：2009-10-21
申请人： MERCK PATENT GmbH , WICKHAM, Thomas , GNAD-VOGT, Ulrike , KLINZ, Stephan G. , HOLDEN, Sylvia A. , KALLEN, Karl Josef
发明人： WICKHAM, Thomas , GNAD-VOGT, Ulrike , KLINZ, Stephan G. , HOLDEN, Sylvia A. , KALLEN, Karl Josef
IPC分类号： A61K38/20
CPC分类号： A61K38/2013 , A61K38/208 , A61N5/10
摘要： The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy.
摘要翻译： 本发明涉及通过在放射治疗后施用免疫细胞因子来治疗肿瘤和癌细胞的方法。 这种治疗组合可以刺激照射和非照射部位的免疫应答，这对于根除从原发肿瘤部位扩散的癌细胞是有用的。 此外，免疫细胞因子可以以小于最大耐受剂量的剂量施用，这降低了与免疫细胞因子疗法相关的副作用。
-
2.发明申请DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS 审中-公开用于预防使用包含蒽环类化疗药物的ERBB2靶向免疫球蛋白治疗的致敏性的剂量和给药
公开(公告)号：WO2012078695A2
公开(公告)日：2012-06-14
申请号：PCT/US2011/063623
申请日：2011-12-06
申请人： MERRIMACK PHARMACEUTICALS, INC. , REYNOLDS, Joseph, G. , OLIVIER, Kenneth, J. , HENDRIKS, Bart, S. , WICKHAM, Thomas , KLINZ, Stephan , GERETTI, Elena
发明人： REYNOLDS, Joseph, G. , OLIVIER, Kenneth, J. , HENDRIKS, Bart, S. , WICKHAM, Thomas , KLINZ, Stephan , GERETTI, Elena
IPC分类号： A61K31/7042 , A61K9/127 , A61P35/00
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/127 , A61K31/704 , A61K31/7042 , A61K47/183 , A61K47/42 , A61K47/6851 , A61K47/6913 , C07K16/32 , G01N33/566
摘要： Methods for determining dosage of HER2-targeted anthracycline -containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2- positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline -containing liposomes.
摘要翻译： 公开了确定含HER2靶向蒽环类抗生素的免疫脂质体的剂量的方法，以及使用如此测定的剂量治疗HER2-阳性肿瘤的癌症患者的方法。 给药时，剂量具有标准剂量的非免疫脂质体（非靶向），含蒽环类脂质体的低心脏毒性特征。
-
3.发明申请DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS 审中-公开用于预防使用包含蒽环类化疗药物的ERBB2靶向免疫球蛋白治疗的致敏性的剂量和给药
公开(公告)号：WO2012078695A9
公开(公告)日：2012-08-09
申请号：PCT/US2011063623
申请日：2011-12-06
申请人： MERRIMACK PHARMACEUTICALS INC , REYNOLDS JOSEPH G , OLIVIER KENNETH J , HENDRIKS BART S , WICKHAM THOMAS , KLINZ STEPHAN , GERETTI ELENA
发明人： REYNOLDS JOSEPH G , OLIVIER KENNETH J , HENDRIKS BART S , WICKHAM THOMAS , KLINZ STEPHAN , GERETTI ELENA
IPC分类号： A61K31/7042 , A61K9/127 , A61P35/00
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/127 , A61K31/704 , A61K31/7042 , A61K47/183 , A61K47/42 , A61K47/48569 , A61K47/48823 , A61K47/6851 , A61K47/6913 , C07K16/32 , G01N33/566
摘要： Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
-
4.发明申请COMPOSITIONS AND METHODS FOR TREATING TUMORS PRESENTING SURVIVIN ANTIGENS 审中-公开用于治疗存在SURVIVIN抗原的肿瘤的组合物和方法
公开(公告)号：WO2007039192A3
公开(公告)日：2008-02-28
申请号：PCT/EP2006009359
申请日：2006-09-27
申请人： MERCK PATENT GMBH , GILLIES STEPHEN D , HETTMANN THORE A O , STEIN PASCAL ANDRE , KLINZ STEPHAN G
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55522 , A61K2039/55527 , C12N2799/022
摘要： The present invention provides vaccine compositions stimulating in a human an immune response to human survivin, thus attacking tumor diseased cells overexpressing survivin. In particular, the present invention provides vaccine compositions comprising peptides derived from non-mammalian survivin as well as from modified mammalian, especially human survivin.
摘要翻译： 本发明提供了刺激人类对人类生存素的免疫应答的疫苗组合物，从而攻击过表达存活蛋白的肿瘤病变细胞。 特别地，本发明提供了包含衍生自非哺乳动物存活素以及来自修饰的哺乳动物，特别是人存活素的肽的疫苗组合物。
-
公开(公告)号：WO2022266357A1
公开(公告)日：2022-12-22
申请号：PCT/US2022/033845
申请日：2022-06-16
IPC分类号： A61K31/33 , C07D403/00 , C07D231/14 , A61K31/41 , A61K31/00
摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
-
公开(公告)号：WO2022266354A1
公开(公告)日：2022-12-22
申请号：PCT/US2022/033841
申请日：2022-06-16
IPC分类号： A61K47/00 , A61K31/165 , A61K31/33 , A61K31/00
摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOLI for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
-
7.发明申请COMPOSITIONS AND METHODS FOR TREATING TUMORS PRESENTING SURVIVIN ANTIGENS 审中-公开用于治疗存在SURVIVIN抗原的肿瘤的组合物和方法
公开(公告)号：WO2007039192A2
公开(公告)日：2007-04-12
申请号：PCT/EP2006/009359
申请日：2006-09-27
申请人： MERCK PATENT GMBH , GILLIES, Stephen, D. , HETTMANN, Thore, A., O. , STEIN, Pascal, André , KLINZ, Stephan, G.
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55522 , A61K2039/55527 , C12N2799/022
摘要： The present invention provides vaccine compositions stimulating in a human an immune response to human survivin, thus attacking tumor diseased cells overexpressing survivin. In particular, the present invention provides vaccine compositions comprising peptides derived from non-mammalian survivin as well as from modified mammalian, especially human survivin.
摘要翻译： 本发明提供了刺激人类对人类生存素的免疫应答的疫苗组合物，从而攻击过表达存活蛋白的肿瘤病变细胞。 特别地，本发明提供了包含衍生自非哺乳动物存活素以及来自修饰的哺乳动物，特别是人存活素的肽的疫苗组合物。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
